Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Meth treatment study explores whether less use, not just no use, improves health

NCT ID NCT07226596

Disease control Sponsor: William Stoops Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether reducing methamphetamine use—without requiring complete abstinence—can improve health and quality of life. Researchers will give 300 adults with methamphetamine use disorder payments for providing drug-free urine samples over 12 weeks. They will measure blood pressure, sleep, and other health markers to see if less use leads to real benefits. The goal is to change how treatment success is measured, making it easier to develop new therapies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Contingency Management (behavioral intervention with payments for negative urine samples)
What this could lead to
If successful, this could show that reducing methamphetamine use (not just quitting) is a valid treatment goal, leading to more flexible and accessible therapies.
What could go wrong
This is an early-stage behavioral study, not testing a drug. Results may not change current treatment standards, and participants may relapse after payments stop.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Jan 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * be age 18 years or older; * self-report methamphetamine use in the week prior to screening; * provide a methamphetamine-positive urine sample at screening; * meet DSM-5 criteria for moderate-severe Methamphetamine Use Disorder (MUD); * be seeking treatment for their methamphetamine use * be able and willing to commit to the 12-week intervention, as well as the 12-week post-intervention follow-up * Individuals who meet these criteria and are stably maintained on buprenorphine or methadone for Opioid Use Disorder (OUD) will also be eligible to participate. Exclusion Criteria: * current or past medical or psychiatric illness (e.g., physical dependence on any drug other than buprenorphine requiring medically managed detoxification, unstable angina, uncontrolled cardiac arrhythmia, aortic stenosis, self-reported compromised immune function, severe diagnosis for a SUD other than MUD or treated OUD) that would interfere with study participation in the opinion of the study physicians * poor venous access precluding blood draws

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Methamphetamine use disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

methamphetamine dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Methamphetamine use disorder

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Psychopharmacology of Addiction Laboratory

    RECRUITING

    Lexington, Kentucky, 40507, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.